SCHEMBL3988152

SCHEMBL3988152

N#Cc1cccc(-c2ccc(Br)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 1/20 0.52
XDH P47989 1/20 0.50
SLC22A12 Q96S37 1/20 0.50
PTPN5 P54829 1/20 0.50
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
PGR P06401 3/20 0.48
GABRG2 P18507 3/20 0.47
GABRB3 P28472 3/20 0.47
GABRA5 P31644 3/20 0.47
GABRA3 P34903 3/20 0.47
MAP4K4 O95819 1/20 0.46
GABRA1 P14867 1/20 0.46
P4HB P07237 1/20 0.45
CHEK1 O14757 1/20 0.45
IDO1 P14902 2/20 0.45
NOTUM Q6P988 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27787243 0.87 CLK4 (0.63) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL783352 0.86 CLK4 (0.53) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL21189130 0.85 CLK4 (0.57) CLK4XDHSLC22A12PTPN5PGR
Hydrochloric Acid SCHEMBL28007259 0.85 CLK4 (0.61) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL2154026 0.85 CLK4 (0.65) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL26910409 0.84 CLK4 (0.52) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL21921980 0.84 CLK4 (0.52) CLK4XDHSLC22A12PTPN5PGR
SCHEMBL29425207 0.83 GABRG2 (0.61) CLK4XDHSLC22A12PTPN5GABRG2
SCHEMBL270874 0.83 GABRG2 (0.61) CLK4XDHSLC22A12PTPN5GABRG2
SCHEMBL29511815 0.82 XDH (0.56) CLK4XDHSLC22A12PTPN5PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50748-E1 Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2026-01-06 US disclosed
CN-113728454-B Compound, organic semiconductor material comprising the same, organic electronic device comprising the same, and display device and lighting device comprising the same 诺瓦尔德股份有限公司 2024-09-24 CN disclosed
US-11827615-B2 Nitrogen-containing compound, electronic element and electronic device SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-11-28 US disclosed
US-11827615-B2 Nitrogen-containing compound, electronic element and electronic device SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-11-28 US disclosed
US-11700768-B2 Compound and organic light emitting device comprising the same LG CHEM, LTD. (KR) 2023-07-11 US disclosed
US-11700768-B2 Compound and organic light emitting device comprising the same LG CHEM, LTD. (KR) 2023-07-11 US disclosed
CN-110177778-B Novel compound and organic light emitting device including the same 株式会社LG化学 2023-06-06 CN disclosed
US-RE49343-E1 Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2022-12-20 US disclosed
US-20220216428-A1 SEE ADDENDUM NOVALED GMBH (DE) 2022-07-07 US disclosed
EP-3726599-B1 COMPOUND, ORGANIC SEMICONDUCTING MATERIAL COMPRISING THE SAME, ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME, AND DISPLAY DEVICE AND LIGHTING DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2022-03-23 EP disclosed
US-20130234119-A1 MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2013-09-12 US disclosed
US-20130234119-A1 MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2013-09-12 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7148226-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. (US) 2006-12-12 US disclosed
US-20060189681-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME AGOURON PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1597246-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2005-11-23 EP disclosed
US-20050176701-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. 2005-08-11 US disclosed
WO-2004074270-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11700768-B2 Compound and organic light emitting device comprising the same ARL1, ARRB1, CRY1 CLK4 2560/4885XDH 201/4885SLC22A12 4141/4885
US-11827615-B2 Nitrogen-containing compound, electronic element and electronic device NOS1, PRMT1, MNS1 CLK4 3808/4885XDH 2195/4885SLC22A12 1931/4885
US-20060189681-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME RNASE1, RNASEH1, NSUN3 CLK4 4124/4885XDH 438/4885SLC22A12 3069/4885
US-20050176701-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same RNASE1, RNASEH1, NSUN3 CLK4 4124/4885XDH 438/4885SLC22A12 3069/4885
US-20220216428-A1 SEE ADDENDUM NECTIN4, GET3, CPNE4 CLK4 892/4885XDH 3705/4885SLC22A12 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.